Writing in The Journal of Nutrition, it was discovered that the supplementation of its palmitoylethanolamide (PEA) ingredient, trademarked Levagen+, might produce anti-inflammatory results in COVID-19 sufferers who weren’t hospitalised.
The four-week medical trial was carried out in Arizona between October 2020 and March 2021 – earlier than COVID-19 vaccines have been rolled out globally.
A complete of 60 topics accomplished the examine the place they have been randomised to take 600mg of Levagen+ or placebo tablets twice each day.
Levagen+ was proven to have considerably lowered the three key inflammatory markers linked to COVID-19, particularly sP-selectin, IL-1β, and IL-2, as in comparison with the placebo.
Talking to NutraIngredients-Asia, R. V. Venkatesh, CEO of Gencor Pacific, mentioned that following the constructive findings, the agency was aiming to place the ingredient for enhancing high quality of life in wholesome people who’ve recovered from COVID-19, however have been nonetheless affected by the signs arising from long-COVID.
“We’re not claiming to forestall or remedy COVID-19, we don’t make a disease-curing declare, however [addressing] what COVID-19 has left behind.
“The chief trigger by which individuals undergo from well being issues post-COVID-19, is because of irritation, and we’re taking a look at that space. Irritation as a result of COVID-19 goes to create way of life issues for individuals,” mentioned Venkatesh.
Examples of those way of life issues embody fatigue, mind fog, an absence of vitality, and discomfort arising from irritation.
“This [Levagen+] could be a good remedy for individuals who have recovered from COVID-19 to regulate irritation,” he mentioned.
He added that there was a market demand for such merchandise because the pandemic has affected a majority of the world’s inhabitants.
“Fairly a major of the world’s inhabitants have recovered from COVID-19, however individuals additionally do get reinfected and are struggling the consequences of COVID-19.”
In the intervening time, the corporate is conducting discussions with regulatory consultants to evaluate the feasibility of the well being claims that it hopes to make with Levagen+ and COVID-19.
“We’re trying totally different markets the place we will make a legally legitimate nutraceutical declare which won’t infringe upon the pharmaceutical space, since nutraceuticals can’t be used for diseased circumstances.”
Extra trials on extra components
Apart from Levagen+, Gencor can be learning how its different trademark components might be useful for put up COVID-19 administration.
One of many components that the agency could be learning is its curcumin ingredient trademarked HydroCurc.
Up to now, three to 4 research have been deliberate and he expects the outcomes to be out finish of this yr or early subsequent yr.
“We’re taking a look at quite a few areas by which we might have a greater high quality of life post-COVID-19,” Venkatesh mentioned.
